NR1H4 and neoplasm: Indeed, many studies have provided evidence that FXR participates in cancer progression and development through distinct mechanisms, and its agonists and antagonists enhance or inhibit tumor cell growth solely or in combination with chemotherapy, targeted therapy, or immunotherapy.